检索结果-南通市图书馆

Evaluation of factors affecting the success rate of orthodontic mini-implants by survival analysis

World Journal of Stomatology 2013年第3期2卷 56-61页

作者： Un-Bong Baik Mohamed Bayome Kwang-Heung Han jae Hyun Park Min-Ho jung Yoon-Ah Kook Smile with Orthodontic Clinic Seoul 142-100 South Korea Department of Orthodontics The Catholic University of Korea Seoul 137-701 South Korea Seoul H Dental Clinic Seoul 150-037 South Korea Postgraduate Orthodontic Program Arizona School of Dentistry and Oral Health A.T. Still University Mesa AZ Graduate School of Dentistry Kyung Hee University Seoul 130-701 South Korea Private practice and Department of Orthodontics School of Dentistry Seoul National University Seoul 151-742 South Korea Department of Orthodontics Seoul St. Mary’s Hospital The Catholic University of Korea Seoul 137-701 South Korea

AIM: To investigate the success rate of mini-implants and its characteristics and risk factors by survival analyses. METHODS: Three hundred and ninety-four miniimplants of the same type were placed by a single clinician. Age, gender, treatment duration, time of failure, side and jaw of implantation and the soft tissue at placement site were recorded. Odds ratio, survival curves, and Cox proportional hazard model were applied to evaluate the factors influencing the miniimplants' success rate. RESULTS: The cumulative success rate was 88.1%.The maxilla had a significantly higher success rate than that of the mandible(91.7% vs 83.7%, respectively, P = 0.019). Placement of mini-implants in the attached gingiva(AG) showed a higher success rate than that of the mucogingival junction(MGJ) and mucous membrane(MM)(AG, 94.3%; MGJ, 85.8%; MM, 79.4%; P < 0.001). Significant association was found between the jaw and the gingival tissue type(P < 0.001). There were no significant differences between maxilla and mandible when compared within each placement ***: The gingival tissue type had the most significant effect on the success rate of the mini-implant with higher success rate in the attached gingiva.

关键词： Mini-implant Success rate Survival analysis Gingival tissue Treatment planning

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Effects of Aroma Acupuncture applied on Chronic Headache Patients

引用

World Journal of Acupuncture-Moxibustion 2005年第3期15卷 35-35页

作者： In Tae jung Su Yong KIM Doo Ik LEE Keon Sik KIM jae Dong LEE Yun Ho LEE Do Young CHOI Research Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni KoreaResearch Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni KoreaResearch Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni KoreaResearch Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni KoreaResearch Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni KoreaResearch Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni KoreaResearch Group of Pain & Neuroscience Vision 2000 Project East-West Medical Research Inst Kyung Hee Uni Korea

Background: Because the cause and etiology of chronic headache is not yet fully explained, the treatment of this symptom is not simple. This study compares the effects of aroma acupuncture and normal acupuncture applied on chronic headache patients, in order to establish a primary data for further studies of new treatments and developments of new practical acupuncture. Methods: 38 clinical experiment participants were gathered and through a questionnaire patients who experienced headache for more than 4 hours a day and more than 15 days per month were qualified as chronic headache patients. The qualified patients were classified into two groups, aroma acupuncture group (Aroma AT group, n=23) and normal acupuncture group (AT group, n=15).

关键词：中医治疗针刺治疗芳香疗法慢性头痛

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

柔性有源OLED显示器制造几点技术方面的考虑

引用

现代显示 2009年第2期 21-24,49页

作者： Juhn S.Yoo Nackbong Choi Yong-Chul Kim In-Hwan Kim Seung-Chan Byun Sang-Hoon jung Jong-Moo Kim Soo-Young Yoon Chang-Dong Kim In-Byeong Kang In-jae Chung 代永平 LG显示公司南开大学

AMOLED在柔性显示领域前途似锦。LG显示展示了一款全彩4in柔性AMOLED样机,衬底为80μm厚的不锈钢薄片,曲率达到5cm弯曲半径。本文就此项柔性显示技术所面临的挑战进行了探讨,包括柔性衬底衬底的传送、如何获得特性稳定可靠的TFT以使OLE... 详细信息

AMOLED在柔性显示领域前途似锦。LG显示展示了一款全彩4in柔性AMOLED样机,衬底为80μm厚的不锈钢薄片,曲率达到5cm弯曲半径。本文就此项柔性显示技术所面临的挑战进行了探讨,包括柔性衬底衬底的传送、如何获得特性稳定可靠的TFT以使OLED的亮度和一致性适用于此项技术的商业化推广。

关键词：有源有机发光二极管柔性显示器电泳显示器

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Successful extracorporeal life support in sudden cardiac arrest due to coronary anomaly

引用

World Journal of Cardiology 2016年第6期8卷 379-382页

作者： jung Wan Park jae Hyuk Lee Ki-Sik Kim Duk Won Bang Min-Su Hyon Min-Ho Lee Byoung-Won Park Department of Internal Medicine Division of CardiologySoon Chun Hyang University Hospital

Extracorporeal life support(ECLS) has recently been reported to have a survival benefit in patients with cardiac arrest. It is now used widely as a lifesaving modality. Here, we describe a case of sudden cardiac arrest(SCA) in a young athlete with an anomalous origin of the right coronary artery from the left coronary sinus. Resuscitation was successful using ECLS before curative bypass surgery. We highlight the efficacy of ECLS for a patient with SCA caused by a rare, unexpected aetiology. In conclusion, ECLS was a lifesaving modality for SCA due to an anomalous coronary artery in this young patient.

关键词： Coronary vessels anomalies Extracorporeal circulation Cardiac arrest

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

一款全新多效气垫粉凝霜的人体功效研究

引用

日用化学品科学 2017年第1期40卷 36-40页

作者：夏雪郭一荣陈雪郑煆镇延在昊爱茉莉太平洋(上海)研发有限公司上海201801

对一种具有全面肤质提升作用的长效气垫粉凝霜进行了功效评价。在广州地区选择21名25~40岁具有彩妆使用习惯的女性,在产品使用前和使用后12 h对皮肤水分、肤色、光泽度、毛孔状况及细纹深度和数量进行了分析;同时考察了使用产品后皮肤... 详细信息

对一种具有全面肤质提升作用的长效气垫粉凝霜进行了功效评价。在广州地区选择21名25~40岁具有彩妆使用习惯的女性,在产品使用前和使用后12 h对皮肤水分、肤色、光泽度、毛孔状况及细纹深度和数量进行了分析;同时考察了使用产品后皮肤表面温度变化情况并就满意度对受试者进行了问卷调查。结果表明,该产品能显著提高肌肤水分,改善肤色,细化毛孔和皮肤纹理,实现较好的遮盖效果并保持长效妆容,并可通过降低皮肤表面温度来提供良好的清凉感。多于85%的受试者对该产品的整体效果表示满意,专业的临床评价也显示该产品安全性高,无受试者出现不良反应。

关键词：气垫粉凝霜改善肤质清凉感长效临床评价

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

边缘区淋巴瘤晚期患者R-CVP后利妥昔单抗维持治疗的Ⅱ期研究:一项改善淋巴瘤生存协会(CISL)的研究

引用

癌症 2020年第3期39卷 118-128页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok‑Hwan Yang Won Sik Lee Hyo jung Kim Ho‑Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung‑Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong‑Won Lee jae Hoon Lee Ho Sup Lee Ho‑Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa‑guSeoul 05505Republic of Korea Department of Hematology‑Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology‑Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology‑Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多... 详细信息

背景与目的利妥昔单抗是一种靶向CD20的单克隆抗体,在治疗边缘区淋巴瘤(marginal zone lymphoma,MZL)中可以单药或联合化疗使用,可提高缓解率和生存率,但治疗后仍可能会复发。因此,仍需探索如何延长MZL患者的缓解期的治疗方案。这项多中心、单臂、开放标签的Ⅱ期研究评估了对一线R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone;利妥昔单抗、环磷酰胺、长春新碱和泼尼松龙)治疗有反应的Ⅲ–Ⅳ期CD20阳性MZL患者进行利妥昔单抗维持治疗2年的生存率。本研究旨在明确R-CVP后利妥昔单抗维持治疗的策略是否有进一步研究的价值。方法在利妥昔单抗维持治疗之前,Ⅲ–Ⅳ期MZL患者应接受6–8周期的R-CVP一线治疗。每个周期为3周,第1 d静脉输注利妥昔单抗(375 mg/m^2)、环磷酰胺(750 mg/m^2)和长春新碱(1.4 mg/m^2;最大2 mg),第1–5 d口服泼尼松龙(100 mg)。对R-CVP治疗达到完全缓解(complete response,CR)、部分缓解(part response,PR)或疾病稳定(stable response,SD)的患者进行利妥昔单抗维持治疗,每8周静脉注射利妥昔单抗375mg/m^2,直到12个周期。主要终点为无进展生存期(progression-free surviva,PFS),次要终点为总生存期(overall survival,OS)和治疗安全性。结果共纳入47例患者,其中45(96%)例接受了利妥昔单抗维持治疗。15(33%)例患者有淋巴结MZL。在进行R-CVP一线治疗后,分别有20(44%)例、22(49%)例和3(7%)例的患者达到了CR、PR和SD。中位随访38.2个月后,患者的3年PFS率为81%。在利妥昔单抗维持治疗期间,R-CVP治疗后有6例PR和1例SD患者获得CR。LDH升高和B症状是PFS的重要预后因素(P=0.003),3年OS率为90%。利妥昔单抗维持治疗的耐受性良好,常见的治疗性不良事件为感觉性神经病(18%)、肌痛(13%)、疲劳(9%)和中性粒细胞减少(9%)。结论一线R-CVP治疗后利妥昔单抗维持治疗在Ⅲ–Ⅳ期MZL患者中不仅表现出较好的PFS,而且药物毒性反应评价良好。

关键词：边缘区淋巴瘤晚期利妥昔单抗环磷酰胺长春新碱维持多中心开放标签生存

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer

引用

肿瘤药学 2023年第6期 644-644页

作者： Yoo-Na Kim Yeeun Shim Jieun Seo Zisun Choi Yong jae Lee Saeam Shin Sang Wun Kim Sunghoon Kim Jong Rak Choi jung-Yun Lee Seung-Tae Lee 李贺

PARPi是基于“合成致死”原理开发的一类药物。由于患者良好的生存获益,目前PARPi维持治疗已经成为卵巢癌患者,尤其是BRCA1/2突变卵巢癌患者的标准治疗方案之一。自2018年奥拉帕利(olaparib)被FDA批准上市以来,PARPi的适应证已经由BRCA...

PARPi是基于“合成致死”原理开发的一类药物。由于患者良好的生存获益,目前PARPi维持治疗已经成为卵巢癌患者,尤其是BRCA1/2突变卵巢癌患者的标准治疗方案之一。自2018年奥拉帕利(olaparib)被FDA批准上市以来,PARPi的适应证已经由BRCA1/2突变型卵巢癌扩大到BRCA1/2野生型但携带同源重组修复缺陷(HRD)表型的卵巢癌、乳腺癌、前列腺癌及胰腺癌。然而,

关键词：

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

新的心肌PET显像剂18F-FPTP的参数图形算法的比较

引用

中华核医学与分子影像杂志 2018年第2期38卷 151-151页

作者：唐军 Ji Who Kim Seongho Seo Hyeon Sik Kim Dong-Yeon Kim Ho-Young Lee Keon Wook Kang Dong Soo Lee Hee-Seung Bom jung-Joon Min jae Sung Lee 上海交通大学医学院附属苏州九龙医院核医学科 Department of Nuclear Medicine and Department of Biomedical Sciences Seoul National University Department of Cardiology Chonnam National University Hwasun Hospital

目的 (18F-氟戊基)三苯基季磷盐(18F-FPTP)是一种新的有应用前景的心肌PET显像剂,其在心肌细胞内积聚量多且肝脏清除快。该研究小组在小鼠体内做了18F-FPTP PET显像的代谢区室分析和两项线性分析,即用于生成参数图的线性最小二乘法（LL... 详细信息

目的 (18F-氟戊基)三苯基季磷盐(18F-FPTP)是一种新的有应用前景的心肌PET显像剂,其在心肌细胞内积聚量多且肝脏清除快。该研究小组在小鼠体内做了18F-FPTP PET显像的代谢区室分析和两项线性分析,即用于生成参数图的线性最小二乘法（LLS）和基函数法（BFM）分析。此外,还研究了动态分析的最小动态显像时间,并进行了计算机模拟。方法对心肌梗死（MI）小鼠模型（n=12）进行18F-FPTP动态PET显像（18 min）和CT显像。在左心室、正常心肌和梗死区勾画感兴趣区（ROI）。比较两室模型（速率常数k1和k2;2室2参数）和不可逆摄取的三室模型（速率常数k1-k3;3室3参数）的拟合优度,并进行部分容积和溢出校正（Vα和α=1-Va）。LLS和BFM用于基于ROI和基于体素的动力学参数估算,估算结果与相应代谢区室模型标准的基于ROI的非线性最小二乘法（NLS）结果进行比较。通过计算机模拟研究估算方法的统计学特点。结果 2室2参数模型最适于描述18F-FPTP的动力学表现。正常心肌的平均k1、k2和Va值分别是6.8ml·min-1·g-1、1.1/min和0.44,而梗死组织的分别是1.4 ml·min-1·g-1、1.1/min和0.32。动态显像10 min的数据即足够用于估算各项参数。LLS和BFM的估算结果与ROI水平的NLS的结果有很好的相关性（k1:1.22x-0.30,r2=0.90;y=1.26x+0.00,r2=0.92）。动态参数图形（αk1,k1,k2,Va）的局部分布具有生理相关性。在计算机模拟中,LLS和BFM比NLS的特征性更强。结论快速的动力学特征和心肌较高的特异性摄取使18F-FPTP能在显像开始的最初10 min动态显像内,利用2室2参数模型进行定量分析。LLS和BFM能在体素水平进行参数估算,这2种方法可用于定量评价18F-FPTP在心肌中的分布,进而研究其在不同条件、不同疾病模型和病种中进行心肌显像的表现。

关键词：定量参数图模拟心肌PET

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

通过13N-NH3 PET检测冠脉血流储备和相对血流储备以诊断冠心病

引用

中华核医学与分子影像杂志 2017年第10期37卷 672-672页

作者：顾佳唐军苏州大学医学部放射医学与防护学院 215123 苏州大学附属第二医院核医学科 215004

目的使用13N-NH，PET显像检测冠脉血流储备（CFR）和相对血流储备（RFR），分析两者之间的关系以诊断冠心病。方法69例稳定性心绞痛患者在2周内接受13N—NH，PET显像和cT冠脉造影（CTA），必要时还行介入冠脉造影（CAG）。通过13N-NH，... 详细信息

目的使用13N-NH，PET显像检测冠脉血流储备（CFR）和相对血流储备（RFR），分析两者之间的关系以诊断冠心病。方法69例稳定性心绞痛患者在2周内接受13N—NH，PET显像和cT冠脉造影（CTA），必要时还行介入冠脉造影（CAG）。通过13N-NH，PET显像检测心肌血流（MBF）、CFR、RFR和相关冠脉供血区域的冠脉血管阻力（CVRref）。采用CTA和CAG评价冠脉明显狭窄（SS）和弥漫性动脉粥样硬化（DA）。比较有和无SS和DA的各冠状动脉的PET检测功能参数。结果有SS和DA的冠状动脉其负荷态MBF显著降低，有SS的冠脉其RFR显著降低，而CFR没有降低。有DA的冠脉其CFR显著降低，而RFR没有降低。在没有SS的冠脉中，有DA的其CFR显著降低，但在有SS的冠脉中，无论有无DA，CFR都相近。相反，无论有无DA，存在SS的冠脉其RFR显著降低。CFR和RFR在24例中（35％）呈不一致的弱正相关性（r=0．269）。在CFR和RFR不一致的冠脉中，CFR降低而RFR正常的冠脉其DA的发生率高于CFR正常而RFR降低的冠脉（75％比25％，P=0．028）。有DA的冠脉其CVR。显著升高，表明DA与潜在的微血管病变具有相关性。结论心肌血流灌注PET显像测定CFR和RFR为诊断CAD提供了更丰富的信息。

关键词：冠心病正电子发射断层显像术冠脉血流储备相对血流储备

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study

引用

Cancer Communications 2019年第1期39卷 526-535页

作者： Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok-Hwan Yang Won Sik Lee Hyo jung Kim Ho-Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee jae Hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 06351Republic of Korea Division of Hematology Department of Internal MedicineYonsei University College of MedicineSeoul 03722Republic of Korea Department of Oncology Asan Medical CenterUniversity of Ulsan College of MedicineSongpa-guSeoul 05505Republic of Korea Department of Hematology-Oncology Chonnam National University Hwasun HospitalHwasun 58128Republic of Korea Department of Hematology Busan Paik HospitalInje University College of MedicineBusan 04511Republic of Korea Department of Internal Medicine Hallym University Sacred Heart HospitalHallym University College of MedicineAnyang 14068Republic of Korea Department of Internal Medicine Chonbuk National University HospitalJeonju 54907Republic of Korea Department of Hematology-Oncology Ajou University School of MedicineSuwon 16499Republic of Korea Department of Internal Medicine Soonchunhyang University Seoul HospitalSoonchunhyang University College of MedicineSeoul 04401Republic of Korea Division of Hematology-Oncology Department of Internal MedicineWonju Severance Christian HospitalYonsei University College of MedicineWonju 26426Republic of Korea Department of Internal Medicine Haeundae Paik HospitalInje University College of MedicineBusan 48108Republic of Korea Division of Hematology and Oncology Department of Internal MedicineSamsung Changwon HospitalSungkyunkwan University School of MedicineChangwon 51353Republic of Korea Division of Hematology-Oncology Department of Internal MedicineDongnam Institute of Radiological and Medical SciencesBusan 46033Republic of Korea Division of Hematology-Oncology Department of Internal MedicineGyeongsang National University HospitalGyeongsang National University College of MedicineJinju 52727Republic of Korea Department of Internal Medicine Gachon University Gil Medical CenterIncheon 21565Republic of

Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment ***,extending the period of remission in MZL patients remains an essential *** multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further ***:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV ***(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week *** patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 *** primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment ***:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance ***(33%)patients had nodal *** R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,*** a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of *** LDH and the presence of B symptoms were found to be significant prognostic fac

关键词： Marginal zone Lymphoma Advanced stage Rituximab Cyclophosphamide Vincristine Maintenance Multicenter Open label Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：